Hormonal
Topical cosmetic peptides (e.g., GHK-Cu, Matrixyl, Argirelin) reduce wrinkles and improve skin firmness with excellent safety profiles, though effects are modest and require consistent long-term use.
Topical peptides like GHK-Cu, Matrixyl, and Argirelin can help reduce wrinkles and improve skin firmness when applied consistently over 8-12 weeks. They are generally safe and well-tolerated, but the effects are modest compared to injectable treatments. Regular use is necessary to maintain benefits.
One study has shown a reduction in fine wrinkles and lines with topical use over 2–4 months [73]. ... In a 12-week clinical trial, Matrixyl 3000 demonstrated a significant reduction in wrinkles and lines, confirmed by silicone replication [69]. ... Pure 10% Argireline has also been shown to significantly reduce forehead wrinkles when applied 2×/day for 30 days (measured by digital image analysis), with approximately 17–20% reduction in dynamic wrinkles [73].
Why this rating
Based on small clinical trials and in vitro studies; effects are modest and variable.
Source
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives
Guilherme Renke et al. · International Journal of Molecular Sciences · 2026
DOI 10.3390/ijms27093890
More from this paper
- Triple-agonist GLP-1/GIP/Glucagon analogs (e.g., retatrutide) produce superior weight loss compared to dual or single agonists by synergistically activating multiple satiety and energy expenditure pathways.Good
- BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.Limited
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →